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A genetic model of malignant phase hypertension in rats. A genetic
model of malignant phase hypertension in rats is described which closely
parallels the natural histoiy of untreated human malignant phase hyper-
tension. Although the factors initiating transition from essential hyperten-
sion to the accelerated phase in humans remain unknown, we report the
characteristics of a genetically determined and reproducible phenotype
which was found to result from a cross between hypertensive transgenic
Ren-2 rats and normotensive Sprague-Dawley (Edinburgh) rats. Male Fl
hybrids developed malignant phase hypertension with a penetrance of
73.5% (95% confidence limits 65.7 to 81.3%) by 100 days of age.
Phenotypic features included an accelerated rise in blood pressure,
fibrinoid necrosis, activation of the renal renin-angiotensin system and
mieroangiopathic hemolytic anemia. In an analytical cross no significant
difference in blood pressure was observed between malignant phase and
non-malignant phase animals prior to transition, implying thata factor in
addition to hypertension appears necessary for inducing transition to the
malignant phase phenotype. Segregation of the malignant phenotype
suggested that susceptibility is determined by at most two genetic loci.
It is estimated that between 1 and 2% of essential hypertensives
develop malignant phase hypertension precipitated by a sudden
rise in blood pressure [1]. This incidence has been reduced from
previous levels by improved management of essential hyperten-
sion [2], but if untreated the mortality from this complication
remains extremely high with a one year survival of less than 10%
[31. The pathological changes affecting the vasculature in malig-
nant hypertension have been well described and include a myo-
intimal proliferative response with endothelial swelling, areas of
fibrin deposition, fibrinoid and cellular necrosis predominantly
affecting small renal arteries and afferent arterioles [4—81. Acti-
vation of the renal renin-angiotensin system (RAS) occurs in
response to the afferent vascular pathology and a pressure in-
duced diuresis and natriuresis [9, 10], and may serve to further
increase blood pressure producing a vicious circle of accelerating
blood pressure (BP) and RAS activation [2]. A microangiopathic
hemolytic anemia results from intravascular hemolysis leading to
the appearance of red cell fragments, spherocytes, microsphero-
cytes and a reticulocytosis [11]. How environmental and genetic
factors might determine susceptibility or induce transition to the
malignant phase are poorly understood, but cigarette smoking
[12], the oral combined contraceptive [13] and HLA type [14]
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have all been implicated. Since there has been no available genetic
model for this disease, animal models of malignant hypertension
have only been made possible by dietary, surgical or pharmaco-
logical manipulation [15—17].
The transgenic rat line TGR(mRen2)27 exhibits sustained
hypertension as a consequence of expression of the mouse Ren2
renin gene in a Hannover Sprague-Dawley (HanSD) rat [18]. The
exact mechanism of the hypertension is not clear but overexpres-
sion of the transgene in adrenal cortex resulting in activation of
the adrenal RAS [19—21], a high circulating prorenin [22], in-
creased vascular wall renin activity [23] and the response to
converting enzyme inhibiton [24] suggest that blood pressure may
well be Ang II dependent. Expected target organ damage is seen
in the kidney and heart of heterozygotes from four to six months
of age [25], but no hallmarks of malignant phase hypertension
have been reported to date. In this study we have used the
presence and function of the Ren2 transgene as a method of
inducing hypertension in three rat strains and have observed a
strain-dependent difference in the incidence of a phenotype
analogous to malignant hypertension which was invariably termi-
nal. Observed features included the adoption of a hunched
posture with extreme lethargy, piloerection, a diuresis with a 5 to
10% loss in body weight occurring over one to three days, and on
occasion unilateral or bilateral seizures or hemiparesis. A second
analytical cross demonstrated that segregation of the phenotype
occurred independent of BP prior to onset of malignant phase,
and was due to one or at most two genetic loci.
Methods
Animals
All animals were housed in identical conditions with a 12:12
hour light-dark cycle, controlled temperature (18 to 20°C) and
humidity (45 to 65%). A normal sodium diet (0.32% sodium
CRM diet, SDS, Witham, Essex, UK) was used with tap water ad
libitum to drink.
Fl hybrids, hemizygous for the Ren2 transgene (Ren2/—) were
derived from crossing male TGR(mRen2)27 homozygotes on a
Hannover Sprague-Dawley (HanSD) background with: (i) female
Edinburgh Sprague-Dawley (EdinSD) (Centre for Genome Re-
search, University of Edinburgh, UK) to give hybrids of genotype
HanRen2/Edin—; (ii) HanSD (Central Institute of Laboratory
Animal Breeding, Hannover, Germany) to give HanRen2/Han—;
and (iii) Lewis rats (Harlan-Olac, Oxford, UK) to give HanRen2/
Lew—. Animals were closely observed for the appearance of
terminal features of the phenotype as described, and were put
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down for humane reasons in accordance with the Animals (Sci-
entific Procedures) Act 1986. Where possible kidney, heart,
descending thoracic aorta, superior mesenteric artery and brain
were removed, fixed in 4% formal saline and paraffin embedded.
Three j.tm sections were stained with hematoxylin and eosin
(H&E) according to standard methods [26]. Control tissues were
obtained from age- and sex-matched healthy transgenic heterozy-
gotes and non-transgenic HanSD and Edin SD. Blood, obtained
by cardiac puncture from malignant phase male HanRen2/Edin(N = 5), and from healthy, hypertensive, age-matched male
HanRen2/Edin littermates (N = 5) under halothane anesthesia
was collected into tubes containing EDTA (Sarstedt Monovette
2.7 ml tubes) before spreading and staining with Wright's stain.
Plasma creatinine was assayed by a colorimetric method (Gemeni,
Electro-nucleonics, Inc., NJ, USA) from blood obtained as above
and collected into lithium heparin (1 ml tube, Teklab M.L. Ltd,
Durham, UK).
Blood pressure
Continuous monitoring of BP in conscious, unrestrained male
rats was performed using telemetry (Data Sciences International,
St. Paul, MN, USA). Implantation of transmitters (TA11PA-C40)
was performed at 37 to 49 days of age by aseptic technique, under
halothane anesthesia (2 to 4% in oxygen), with placement of the
catheter tip in the aorta distal to the origin of the renal arteries.
Rats were housed singly in cages above a RA 1010 receiver pad.
Receivers were connected to a BCM100 consolidation matrix and
signals transmitted to a Dataquest IV acquisition system. BP was
corrected for atmospheric pressure. Systolic (SBP), mean (MBP)
and diastolic (DBP) pressures were collected at 10 minute inter-
vals after recovery from surgery. Twenty-four hour MBP (group
mean and SEM) for male HanRen2/Edin— (N = 10), HanRen2/
Han— (N = 6), HanRen2/Lew— (N = 4), EdinSD (N = 3),
HanSD (N = 3) and Lewis (N = 4) was recorded from 46 to 90
days of age.
Renin-angiotensin system parameters
Plasma renin activity (PRA), angiotensin II (Ang II) and
aldosterone were measured by radioimmunoassay, by methods
described elsewhere [27—29], in healthy seven to nine-week- old
HanRen2/Edin—, HanRen2/Han—, HanRen2/Lew—, non-trans-
genic controls (EdinSD, HanSD, Lewis) and malignant phase
Ren2 hemizygotes. Blood, obtained by retro-orbital bleeding or
cardiac puncture under halothane anaesthesia, was collected into
pre-chilled tubes on ice: in lithium heparin (1 ml tube, Teklab
M.L. Ltd, Durham UK) for PRA; in inhibitor (1 pi/ml) 1,10
phenanthroline monohydrate (Sigma, UK) in EDTA (BDH Lab-
oratory Supplies, UK) for Ang II; or for aldosterone determina-
tion, with no anticoagulant, spun at 4000 g at 4°C for 10 minutes
to obtain plasma or serum and samples were stored at —70°C
before assay. Immunostaining for renin was performed on 3 im
de-paraffinized sections of kidney (fixed in 4% formal saline). A
rabbit anti-mouse renin primary antibody (cross reacts with rat)
was applied, with an avidin-biotin horseradish peroxidase second-
ary detection system (Vectastain, Vector Laboratories, Inc., Bur-
lingame, CA, USA). Primary antibody was omitted as a negative
control.
Analytical cross
Seventy-three male Fl progeny (Edin,Han)Ren2/(Edin,Lew)—
were bred from three (Han,Edin)Ren2/(Han,Edin)Ren2 males
(derived from a HanRen2/Edin intercross) and seven Edin—/
Lewis— females and housed and maintained as described above.
Animals were examined for the terminal features suggestive of
malignant phase hypertension as described, and diagnosis was
confirmed postmortem by the presence of fibrinoid necrosis on
light microscopy of 3 m kidney sections (H&E stain). SBP was
measured by tail cuff plethysmography (Model 179 blood pressure
analyzer, Model 27 cuff pump, IITC Life Science Instruments,
Norfolk, UK) under light halothane anaesthesia (2% in oxygen)
on a heating pad (33°C), in all 73 rats at 52 days and measured
weekly in a subgroup of 28 rats from 35 days.
Statistics
Blood pressures are shown as group means and SEM. Student's
t-test was used for unpaired comparisons of group means at each
time point with the Bonferroni correction for multiple compari-
sons where appropriate. Statistical comparisons made between
malignant phase and each non-malignant phase group for PRA,
Ang II and aldosterone levels were performed using unpaired
t-tests with Bonferroni correction. Penetrance of the phenotype in
crosses is shown with 95% confidence limits. The x2 test was used
to compare penetrance of the malignant phenotype in the progeny
of the analytical cross, (Edin,Han)Ren2/(Edin,Lew)— with that in
HanRen2iEdin—. Observed penetrance and expected levels of
penetrance (with 95% confidence intervals) if one, two or three
genes were operating were also compared using test. The level
of statistical significance was taken to be P < 0.05.
Results
Characterization of the phenotype
The spontaneous development of an altered phenotype in
TGR(mRen2)27 heterozygotes was observed on crossing HanSD
males homozygous for the Ren2 transgene (genotype HanRen2/
HanRen2) with EdinSD (genotype Edin—/Edin—). Animals
were noted to have a diuretic phase resulting in up to 10% loss in
body weight over one to three days. They adopted a hunched
apathetic posture, with evidence of unilateral seizures or hemipa-
resis in a minority. Death occurred between 33 and 103 days
(median 57 days) of age in males and between 46 and 103 days
(median 62 days) in females.
Three different Fl hybrid groups resulting from crossing ho-
mozygote HanRen2/HanRen2 with EdinSD, HanSD, or Lewis
were compared for incidence of the phenotype in males and
females on a 0.32% sodium diet, and maintained in identical
conditions (Table 1). HanRen2/Edin— showed the highest inci-
dence with the phenotype affecting 73.5% of males (65.7 to 81.3%,
95% confidence interval), and 52.5% (44.7 to 60.3%) of females.
For HanRen2/Han—, 18% (6 to 30%) of males and 4% (0 to
10%) of females were affected. No HanRen2/Lew— males or
females developed the phenotype.
Histopathology of kidney from affected animals demonstrated
both myointimal proliferation and fibrinoid necrosis, particularly
affecting afferent arterioles, interlobular arteries and occasional
glomerular tufts (Fig. 1, A-D). Changes indicative of chronic
ischemic damage or long standing hypertension were not a feature
in transgenic heterozygotes up to 12 weeks of age. Microscopic
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myocardial infarcts were found, occasionally seen to be related to
fibrinoid necrosis of cardiac arterioles. Early lesions appeared as
collections of cardiomyocytes showing evidence of focal necrosis,
but granulation tissue and focal fibrotic scars suggested that a
healing response did occur. Cerebral hemorrhage and infarction
occurred infrequently and no significant pathology of either aorta
or superior mesenteric artery was seen in the malignant phase
(data not shown). All blood films from malignant phase HanRen2/
Edin— (N = 5) exhibited microangiopathic hemolytic anemia
with red cell fragments, spherocytes, microspherocytes and reticu-
locytosis, while films from age-matched controls (non-malignant
HanRen/Edin— littermates (N 5) showed no features of
hemolysis (Fig. 1 E, F). Renal failure accompanied the clinical
features with elevation of plasma creatinine (measured in 8
affected animals) to a mean of 111.9 tmolIliter (range 59 to 239
mol/liter) compared with a mean of 41.4 mol/liter (22.8 to 60.0
tmol/liter, 95% confidence limits) for healthy but hypertensive
age-matched transgenic heterozygotes (N 55).
An accelerated rise in MBP occurred in heterozygotes who died
from malignant phase hypertension (N = 5) while on telemetry
with a mean increase of 72 mm Hg (range 65 to 75mm Hg)
occurring over the terminal six hours (Fig. 2A). MBP measured in
the three Fl hybrids and in non-transgenic strains, EdinSD,
HanSD and Lewis is illustrated in Figure 2B. HanRen2/Edin—
showed a significantly higher MBP, from 52 to 60 days compared
to either HanRen2/Han— or HanRen2/Lew— (P < 0.01), but on
attaining the plateau phase at 70 days the MBP SEM for
HanRen2/Han— and HanRen2/Lew— were 169 11.9 and 177.3
4.1 mm Hg respectively, which was not significantly different to
the MBP SEM of HanRen2/Edin— at 60 days (180.7 10.0 mm
Hg), around the median age for onset of malignant phase. No
significant difference in MBP was seen between non-transgenic
strains.
PRA, Ang II and aldosterone levels in plasma were significantly
elevated in the malignant phase compared to both age-matched
non-malignant transgenic heterozygotes and non-transgenic con-
trols (Fig. 3A). Immunostaining of kidney sections using an
anti-mouse renin antibody which cross reacts with rat renin
showed marked, but selective, staining of afferent arterioles at the
vascular poles of glomeruli from malignant phase kidneys (Fig.
3B). Little renin staining was seen in healthy hypertensive age/sex
matched hybrids, relative to both non-transgenics (not shown) as
previously described [25], and malignant phase transgenic rats.
Analytical cross
A segregating cross for EdinSD alleles was designed (Fig. 4A).
Seventy-three hybrid males of genotype (Han,Edin)Ren2/ (Edin,
Lew)— were bred. Forty-two out of seventy-three (57.5%, 95%
confidence limits 45.9 to 69.5%) developed signs of malignant
phase hypertension, verified by the presence of fibrinoid necrosis
on light microscopy of H&E stained kidney sections, and died
between 53 and 103 days (median 66 days). This incidence was
significantly different to that observed in HanRen2/Edin— (=
5.181, df = 1,P <0.05). Expected levels of penetrance if one, two
or three genetic loci were involved were calculated, as discussed
below, and compared with the observed penetrance in the cross.
The results most closely fit a monogenic model where expected
penetrance would be 55.1% (95% confidence interval 49.3 to
61%).
SBP was measured in all 73 rats by tail cuff plethysmography at
Table 1. Fl hybrids, hemizygous for the Ren2 transgene were derived
from crossing male TGR(mRen2)27 homozygotes on a HanSD
background with female EdinSD, HanSD and Lewis rats giving the
genotypes shown
Incidence of Malignant
hypertension
Heterozygote cross Genotype Male Female
HanRen2 X Edin SD HanRen2/Edin— 86/117 (73.5%) 83/158 (52.5%)
HanRen2 >< Han SD HanRen2/Han— 7/39 (18%) 2/44 (4%)
HanRen2 X Lewis HanRen2/Lew— 0/35 (0%) 0/31 (0%)
The incidence (percentage) of male and female progeny developing
malignant phase hypertension for each cross on a normal diet is shown.
52 days of age and weekly in a subset of 28 rats from 35 days of age
(Fig. 4B). At 52 days there was no significant difference in SBP
between those rats destined to develop malignant hypertension
and those who did not (mean SEM, 193.0 4.8 mm Hg and
182.8 4.8 mm Hg, respectively, P = 0.278), but at 35 days a small
but significant difference did exist (malignant phase 141.9 5.6
mm Hg and non-malignant phase 124.2 4.6 mm Hg, P 0.02).
Discussion
The phenotype described above appears to be an excellent
experimental model exhibiting within a defined age range all the
main clinical characteristics of malignant phase hypertension,
namely an accelerated rise in blood pressure, diuresis, impaired
renal function, activation of the renal RAS, microangiopathic
hemolytic anemia and the classical pathological changes of myo-
intimal proliferation and fibrinoid necrosis. Some variation in the
severity of pathological, biochemical and immunological change
measured is to be expected due to the necessity for intervention
for humane reasons when animals were showing signs of terminal
malignant phase, as samples were therefore obtained at varying
stages during the natural history of the established phenotype.
Malignant phase hypertension is arising in a model where
expression of the Ren-2 transgene has been used as a tool to
elevate blood pressure, but without requiring dietary, surgical or
pharmacological manipulation or selective breeding, an increased
tendency for spontaneous transition to malignant phase is exhib-
ited in certain animals. Although the underlying hypertension in
this rat model may well be Ang II dependent, activation of the
renal RAS system is seen during malignant phase. Elevated
plasma renin, increasing Ang II and resulting hyperaldosteronisni
is thought to be central to the process of MH providing the drive
for further BP elevation [30—32]. In animal models, infusion of
renin and aldosterone induced typical pathological changes [33],
though while Ang II infusion in rabbits did cause acute renal
failure and tubular necrosis, arteriolar changes were not observed
[34]. In salt loaded SHR-SP, both ACE inhibition and the specific
Ang II antagonist, Losartan, slowed both the rise in BP and
prevented or delayed the development of renal arterial necrosis
[35, 36].
Factor(s) provided by the genetic background appear to be
acting in concert with "benign hypertenion" to induce the change
in phenotype. Environmental factors do not play a major role as
shown by the differing incidence of the malignant phenotype in
the three transgenic hemizygote hybrids tested (HanRen2/Edin—,
HanRen2/Han— and HanRen2/Lew—), despite maintenance in
identical conditions. The reason for the difference in incidence
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Fig. 3. PRA, Ang II and aldosterone were
measured by radioimmunoassay in 7- to 9-week-
old healthy (U) HanRen2/Edin— (N = 15,11,14
for each assay respectively);
HanRen2/Han— (N = 19,11,30); ()
HanRen2/Lew— (N = 14,12,19); () pooled
non-transgenic EdinSD/HanSD/Lewis (N =
18,14,13); (LII) and malignant phase Ren2
hemizygotes (N = 14,11,15). Results are shown
as group means SD. Significantly higher
values were seen for PRA(*P < 0.008), Ang II(tP < 0.04) and aldosterone (*P < 0.004) in
the malignant phase compared to the other 4
non-malignant groups (unpaired t-test with
Bonferroni correction). B. Irnmunostaining of 3
sm kidney sections using an anti-mouse renin
antibody which cross reacts with rat shows (1)
rat glomerulus (g) (X 400) from malignant
phase Ren2 hemizygote demonstrating dense
immunostaining of the afferent arteriole (aa) at
the vascular pole, but (2) little staining of the
vascular pole (aa) is seen in the non-malignant
phase transgenic littermate (X 630).
between male and female strains has not been addressed in this
study. Small variations in dietary sodium (0.32% vs. 0.2%) did not
influence either MBP or survival in telemetered transgenic het-
erozygotes [371. Therefore, if genetic factors are important these
might take the form of either loci leading to an increase in
baseline BP or act by some other mechanism independent of BP.
There was no significant difference in MBP between telemetered
EdinSD and HanSD as shown. In addition, a larger group of
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Fig. 1. Kidney, heart, brain, aorta and mesenteric artety was fixed in 4% fo,mal saline, paraffin-embedded and 3 tins sections were stained with hematorylin and
eosin. A. Normal kidney from SD (x 100) showing glomerulus (g). B. Fibrinoid necrosis and C. myointimal proliferation in HanRen2/Edin— kidney (X 100).
D. Illustrates a microscopic infarct in heart (x 100). Blood films (Wright's stain, x 630) E and F show a normal film from a healthy hypertensive
HanRen2/Edin—, and microangiopathic hemolytic anemia with reticulocytosis, red cell fragments, and spherocytes from the malignant phase, respectively.
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Fig. 2. A. Examples of recordings of MB? by telemetry from an individual HanRen2/Han— (—) with chronic hypertension and a HanRen2/Edin— (-.)
with malignant phase hypertension. B. MBP (24 hraverage) as recorded by telemetry was plotted every 2 days for clarity as group mean SEM Starting
from 46 to 52 days of age for: (N) HanRen2/Edin— (N = 10); (•) HanRen2/Han— (N = 6); (A) HanRen2/Lew (N = 4); (Eli) EdinSD (N 3); (0)
HanSD (N = 3); and (A) Lewis (N = 3).
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EdinSD and HanSD rats (N = 11 to iS per group) had weekly tail
cuff plethysmography performed under light halothane anesthesia
from 35 to 90 days of age, and a slightly higher SBP was observed
in HanSD compared to EdinSD [37].
HanRen2/Edin— showed the highest incidence of the malig-
nant phenotype with a penetrance of 73.5% (65.7 to 81.3%), and
did show a significantly higher MBP at 57 days (median age of
death) compared to MBP in the other two groups at that age, but
it was not significantly different to MBP of 70-day-old HanRen2/
Han— or HanRen2/Lew—. Therefore absolute MBP may not be
the critical factor precipitating the transition, but a higher blood
pressure in younger rats may well be a marker of predisposition.
Fig. 4. A. Seventy-three male Fl progeny,
genotype (Edin,Han)Ren2/(Edin, Lew)— were
bred from three (Han,Edin)Ren2/(Han,Edin)Ren2
males (derived from a HanRen2/Edin—
intercross) and seven Edin—/Lew—- females. At
the gamete stage the probabilities of carrying
EdinSD (pE), HanSD (pH) and Lewis (pL)
alleles are shown. The probability of at least
one allele for any locus being derived from
EdinSD (pE) in the (Edin,Han)Ren2/ (Edin,
Lew)— progeny is therefore 3/4 or 75%. B.
SBP was measured weekly by tail cuff
plethysmography under light halothane
anethesia in 28 of the progeny from 35 days of
age and in all 73 rats at 52 days. The number of
those destined to develop malignant (M, N)
and non-malignant phase (NM, A) is shown for
each time point. At 35 days, there was a small
hut significant difference (*P = 0,02).
To test for the possibility of genetic susceptibility to malignant
phase hypertension, a segregating cross for EdinSD alleles was
designed. The incidence of the malignant phenotype, as defined
by the onset of the described signs and confirmed by the presence
of fibrinoid necrosis was 42 of 73 or 57.5% (45.9 to 69.5%) which
was significantly different to the incidence seen in HanRen2/
Edin—, but the age range (53 to 103 days) and median age (66
days) of affected animals was similar. SBP measured just before
the expected time of onset of malignant phase (52 days) did not
differ between malignant and non-malignant rats, but significantly
higher SBP was observed in those destined to develop malignant
phase hypertension at 35 days old.
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The probability of at least one EdinSD derived allele being
present at a given locus in the studied progeny is 3/4, thus if one
dominant gene was responsible an expected penetrance would be
55.1% (95% confidence interval 49.3 to 61%), being 3/4 of 73.5%
which is close to that observed. If two genes were involved, then
the probability of EdinSD alleles being present at both loci would
be 9/16, and hence the expected incidence would be 41.3% (95%
confidence interval 36.9 to 45.7%). Two loci cannot be excluded at
the present time as the upper limit of expected penetrance is not
significantly different to that observed (x2 ranging from 2.028 to
6.18 for 1 df; P ranging from 0.01 to >0.05). Three genes can be
excluded, the expected incidence being 22.6/73 or 31% (27.7 to
34.3%, ranging from 7.972 to 11.706; P < 0.01). These results
therefore most strongly support a monogenic model.
In conclusion, the spontaneous transition to malignant phase
hypertension depends on either one or at most, two loci which
confer susceptibility. A phenotypic marker of predisposition may
be higher BP at a younger age, but absolute BP does not appear
to be the single critical factor in precipitating transition. We
speculate that an additional genetic factor is interacting with a
rising BP, perhaps at the level of the endothelium, and is
responsible for the stimulus initiating the transition into MH and
allowing RAS activation. We believe that the HanRen2/Edin—
cross offers a useful and clinically relevent model to study factors
responsible for initiating malignant phase hypertension and its
pathological sequelae, and will facilitate genetic mapping of the
locus(ci) responsible.
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Appendix. Abbreviations
Ren2 - Mouse Ren2 renin transgene; BP - blood pressure; SBP -systolic
blood pressure; MBP - mean blood pressure; RAS - renin-angiotensin
system; PRA - plasma renin activity; Ang II - angiotensin II; EdinSD -
Sprague-Dawley (Edinburgh strain); HanSD - Sprague-Dawley (Han-
nover strain); df - degrees of freedom.
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